Protara Therapeutics (TARA) Current Assets (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Current Assets data on file, last reported at $140.0 million in Q1 2026.

• On a quarterly basis, Current Assets rose 10.64% year-over-year to $140.0 million in Q1 2026; TTM through Mar 2026 was $140.0 million, a 10.64% increase from a year earlier, with the FY2025 full-year figure at $159.5 million, down 7.35% from the prior year.
• Current Assets for Q1 2026 stood at $140.0 million, down from $159.5 million in the prior quarter.
• Over the last five years, Current Assets for TARA reached as high as $172.2 million in Q4 2024 and fell as low as $57.9 million in Q1 2024.
• Historically, Current Assets has averaged $105.7 million across 5 years, with a median of $94.6 million in 2023.
• On a YoY basis, Current Assets climbed as much as 150.57% in 2024 and fell as far as 38.79% in 2024.
• Year by year, Current Assets stood at $86.1 million in 2022, then fell by 20.25% to $68.7 million in 2023, then soared by 150.57% to $172.2 million in 2024, then slipped by 7.35% to $159.5 million in 2025, then fell by 12.23% to $140.0 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $140.0 million in Q1 2026, $159.5 million in Q4 2025, and $135.6 million in Q3 2025.